Effect of ruboxistaurin on albuminuria and estimated GFR in people with diabetic peripheral neuropathy: Results from a randomized trial

American Journal of Kidney Diseases

Volumn 65, Issue 4, 2015, Pages 634-636

  Tuttle, Katherine R ^a   McGill, Janet B ^b   Bastyr, Edward J ^c   Poi, Keri Kles ^c   Shahri, Nazila ^d   Anderson, Pamela W ^c  

^a Providence Health Care   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RUBOXISTAURIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C BETA;

ADULT; ALBUMINURIA; BLOOD PRESSURE; CREATININE URINE LEVEL; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PROTEIN DIET; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE;

ADULT; ALBUMINURIA; CREATININE; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEIN KINASE C BETA; TREATMENT OUTCOME;

EID: 84926417808     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.11.024     Document Type: Letter

References (9)

1. D. Koya, M.R. Jirousek, and Y.W. Lin Characterization of protein kinase C-β isoform activation on the expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats J Clin Invest 100 1997 115 126
2. T. Inoguchi, R. Battan, E. Handler, J.R. Sportsman, W. Heath, and G.L. King Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation Proc Natl Acad Sci U S A 89 1992 11059 11063
3. E.J. Bastyr, C. Cheng, K.L. Price, K.A. Kles, V. Skljarevski, A. Lledo for the Ruboxistaurin Treatment of DPN Study Group Lack of diabetic peripheral neuropathy (DPN) progression after three years in patients with early mild DPN: experience from the ruboxistaurin clinical trial. Oral presentation, Amsterdam, Netherlands, EASD 2007 Diabetologia 50 suppl 1 2007 S62
4. D. Koya, M. Haneda, and H. Nakagawa Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes FASEB J 14 2000 439 447
5. D.J. Kelly, Y. Zhang, and C. Hepper Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension Diabetes 52 2003 512 518
6. K.R. Tuttle, E.C. Johnson, and S.K. Cooney Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C Kidney Int 67 2005 953 968
7. K.R. Tuttle, G.L. Bakris, R.D. Toto, J.B. McGill, K. Hu, and P.W. Anderson The effect of ruboxistaurin on nephropathy in type 2 diabetes Diabetes Care 28 2005 2686 2690
8. R.E. Gilbert, S.A. Kim, and K.R. Tuttle Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and type 2 diabetes Diabetes Care 30 2007 995 996
9. K.R. Tuttle, J.B. McGill, D.J. Haney, T.E. Lin, P.W. Anderson and the PKC-DRS, PKC-DMES, and PKC-DRS 2 study groups Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease Clin J Am Soc Nephrol 2 2007 631 636